| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
|---|
|
| | | IP | | A | Sufenta | 5 1 ampoule(s) à 2 ml | | | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | ● A+ | FB | | G |  |
| | | IP | | A | Sufenta | 5 1 ampoule(s) à 10 ml | | | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | ● A+ | FB | | G | |
| | | IP | | A | Sufenta forte | 5 1 ampoule(s) à 1 ml | | | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | A | Sufenta forte | 5 1 ampoule(s) à 5 ml | | | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | | Sufenta | 10 x 2 ml | | | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | | Sufenta | 10 x 10 ml | | | k.A. | | Injection solution: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | | Sufenta forte | 10 x 1 ml | | | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
| | | IP | | | Sufenta forte | 10 x 5 ml | | | k.A. | | Injection solution: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | | G | |
